UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: breast cancer
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 827806
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
